Miller Value Partners
TEVA icon

Miller Value Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Miller Value Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,950
Closed -$241K – 37
2024
Q4 		$241K Hold
10,950
– – 0.1% 31
2024
Q3 		$197K Hold
10,950
– – 0.11% 29
2024
Q2 		$178K Sell
10,950
-650
-6% -$10K 0.11% 28
2024
Q1 		$164K Sell
11,600
-1,800
-13% -$22.7K 0.1% 30
2023
Q4 		$140K Sell
13,400
-825
-6% -$7.7K 0.08% 42
2023
Q3 		$145K Sell
14,225
-67,912
-83% -$632K 0.09% 45
2023
Q2 		$618K Sell
82,137
-3,847,647
-98% -$31.2M 0.41% 37
2023
Q1 		$34.8M Sell
3,929,784
-1,217,243
-24% -$12M 2.17% 23
2022
Q4 		$46.9M Sell
5,147,027
-4,107,848
-44% -$35.8M 3.03% 11
2022
Q3 		$74.7M Sell
9,254,875
-79,715
-0.9% -$705K 4.54% 4
2022
Q2 		$70.2M Sell
9,334,590
-724,149
-7% -$6.31M 3.57% 9
2022
Q1 		$94.5M Buy
10,058,739
+399,220
+4% +$3.33M 3.04% 8
2021
Q4 		$77.4M Sell
9,659,519
-88,610
-0.9% -$800K 2.12% 21
2021
Q3 		$94.9M Sell
9,748,129
-1,187,654
-11% -$11.1M 2.2% 12
2021
Q2 		$108M Buy
10,935,783
+381,718
+4% +$4.04M 2.58% 13
2021
Q1 		$122M Buy
10,554,065
+3,414,365
+48% +$39.2M 3.15% 6
2020
Q4 		$68.9M Sell
7,139,700
-953,998
-12% -$9.14M 2.1% 19
2020
Q3 		$72.9M Buy
8,093,698
+243,226
+3% +$2.57M 2.62% 11
2020
Q2 		$96.8M Sell
7,850,472
-67,890
-0.9% -$768K 4.3% 4
2020
Q1 		$71.1M Sell
7,918,362
-1,915,705
-19% -$19.6M 4.57% 2
2019
Q4 		$96.4M Buy
9,834,067
+1,342,915
+16% +$12M 3.42% 7
2019
Q3 		$58.4M Buy
8,491,152
+1,990,900
+31% +$15.3M 2.35% 19
2019
Q2 		$60M Buy
6,500,252
+1,957,720
+43% +$23.6M 2.28% 21
2019
Q1 		$71.2M Buy
4,542,532
+630,730
+16% +$11.1M 2.82% 16
2018
Q4 		$60.3M Buy
3,911,802
+6,350
+0.2% +$130K 2.74% 13
2018
Q3 		$84.1M Buy
3,905,452
+1,316,840
+51% +$30.6M 2.72% 14
2018
Q2 		$63M Buy
2,588,612
+393,640
+18% +$8.03M 2.35% 17
2018
Q1 		$37.5M Buy
2,194,972
+1,678,860
+325% +$32.8M 1.56% 29
2017
Q4 		$9.8M Buy
+516,112
New +$7.76M 0.42% 37

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ion Asset Management
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
Clal Insurance
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return
Phoenix Financial
Phoenix Financial Givatayim, Israel $14.8B AUM 42.86% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Miller Value Partners's TEVA Position: Q1 2025 in Review

Miller Value Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2025, closing a stake of 10,950 shares — an estimated $241K sold.

Miller Value Partners first reported a position in TEVA in Q4 2017 and held it in 29 quarters. The position peaked at $122M in Q1 2021. 565 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Miller Value Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2025 after selling out during the quarter.
  • Miller Value Partners sold 10,950 Teva Pharmaceutical Industries Limited shares in Q1 2025, an estimated $241K.
  • Miller Value Partners first reported a position in Teva Pharmaceutical Industries Limited in Q4 2017 and held it in 29 quarters.
  • Miller Value Partners's Teva Pharmaceutical Industries Limited position peaked at $122M in Q1 2021.
  • 565 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2025.

Based on Miller Value Partners's 13F filing for Q1 2025, filed 15 May 2025.